Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Middle East Conflict Impacts Australia and New Zealand Businesses 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
SAN DIEGO, May 08, 2018 -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report its first quarter financial results on Monday, May 14, 2018 before the open of the U.S. financial markets. Company management will host a conference call and webcast on Monday, May 14, 2018 at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time to discuss the results and provide a corporate update.
Interested parties may access the call by dialing toll-free (844) 358-9116 from the US or (209) 905-5951 internationally and using conference ID 8255679.
The press release and links to a live audio webcast and replay may be accessed on the aTyr website events page at: http://investors.atyrpharma.com/events-and-webcasts. An audio replay will be available for at least 90 days following the event.
About aTyr Pharma
aTyr Pharma is engaged in the discovery and development of innovative medicines using its knowledge of newly discovered pathways in immunology effected by extracellular tRNA synthetases. To date, aTyr has generated innovative and unique development programs based on its knowledge of extracellular histidyl-tRNA synthetase (HARS), known as the Resokine pathway. aTyr’s clinical stage ATYR1923 candidate is an agonist of the Resokine pathway designed to temper immune engagement in interstitial lung diseases. aTyr’s preclinical research stage ORCA program, targets a novel, proprietary immuno-oncology pathway using antibodies to enhance the immune response in tumor settings. aTyr has built an intellectual property estate, to protect its pipeline, comprising over 250 issued patents or allowed patent applications that are owned or exclusively licensed, including over 300 potential protein compositions derived from tRNA synthetase genes. For more information, please visit http://www.atyrpharma.com.
IMMEDIATE RELEASE
Contact:
Mark Johnson
Sr. Director, Investor Relations
[email protected]
858-223-1163
